Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Relay Therapeutics Inc. Common Stock (RLAY) vs Global X Uranium ETF (URA) Price & Performance

Relay Therapeutics Inc. Common StockTrade
Global X Uranium ETFTrade

Price performance (Past 24H)

Key statistics

Relay Therapeutics Inc. Common Stock vs Global X Uranium ETF — how do they compare? Relay Therapeutics Inc. Common Stock trades at $18.03 (market cap $3.82B), while Global X Uranium ETF trades at $38.89 (market cap $5.48B). The key difference: Global X Uranium ETF is the larger of the two by market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Relay Therapeutics Inc. Common Stock for 0 Days and Global X Uranium ETF for 62 Days on average.

RLAYURA
Market Cap
$3.82B$5.48B
Volume
4,332,0795,287,170
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$20.75$61.81
52-Week Low
$6.03$37.52
Typical Hold Time
0 Days62 Days
Enterprise Value
$2.93B—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Relay Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Global X Uranium ETF

URA (Global X Uranium ETF) is trading at $38.96, down 2.43% today amid bearish technical signals. The ETF faces selling pressure with 19 sell signals versus 3 buy signals across technical indicators. Recent news highlights nuclear energy's growth potential from AI power demand and government support, though uranium ETFs have experienced volatility. The fund provides diversified exposure to uranium miners, utilities, and nuclear infrastructure companies.

The nuclear sector shows long-term potential driven by AI energy demands and government investments, but URA faces near-term technical headwinds. Key risks include commodity price volatility and concentrated holdings. Analyst sentiment remains mixed with some seeing value after recent declines while others caution about sector-specific challenges.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RLAY
100% Buy0% Sell
Avg holding period · 0 Days
URA
100% Buy0% Sell
Avg holding period · 62 Days

Top news

Latest headlines on both assets

About Relay Therapeutics Inc. Common Stock

Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.

Read more on RLAY →

About Global X Uranium ETF

URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.

Read more on URA →